PD-1 drugs for Gastric Cancer
7 tracked PD-1 drugs in the Gastric Cancer race. The class explanation lives on the PD-1 page; the full indication pipeline across every mechanism is on the Gastric Cancer page.
5 approved / phase 42 Phase 3
Head-to-head evidence: Camrelizumab vs Nivolumab · Camrelizumab vs Pembrolizumab · Nivolumab vs Opdivo Qvantig · Nivolumab vs Pembrolizumab · Nivolumab vs Pembrolizumab berahyaluronidase alfa · Nivolumab vs Serplulimab